Cargando…
CACNB2 Is a Novel Susceptibility Gene for Diabetic Retinopathy in Type 1 Diabetes
Diabetic retinopathy is a common diabetes complication that threatens the eyesight and may eventually lead to acquired visual impairment or blindness. While a substantial heritability has been reported for proliferative diabetic retinopathy (PDR), only a few genetic risk factors have been identified...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804633/ https://www.ncbi.nlm.nih.gov/pubmed/31439644 http://dx.doi.org/10.2337/db19-0130 |
_version_ | 1783461239681187840 |
---|---|
author | Vuori, Nadja Sandholm, Niina Kumar, Anmol Hietala, Kustaa Syreeni, Anna Forsblom, Carol Juuti-Uusitalo, Kati Skottman, Heli Imamura, Minako Maeda, Shiro Summanen, Paula A. Lehto, Markku Groop, Per-Henrik |
author_facet | Vuori, Nadja Sandholm, Niina Kumar, Anmol Hietala, Kustaa Syreeni, Anna Forsblom, Carol Juuti-Uusitalo, Kati Skottman, Heli Imamura, Minako Maeda, Shiro Summanen, Paula A. Lehto, Markku Groop, Per-Henrik |
author_sort | Vuori, Nadja |
collection | PubMed |
description | Diabetic retinopathy is a common diabetes complication that threatens the eyesight and may eventually lead to acquired visual impairment or blindness. While a substantial heritability has been reported for proliferative diabetic retinopathy (PDR), only a few genetic risk factors have been identified. Using genome-wide sib pair linkage analysis including 361 individuals with type 1 diabetes, we found suggestive evidence of linkage with PDR at chromosome 10p12 overlapping the CACNB2 gene (logarithm of odds = 2.73). Evidence of association between variants in CACNB2 and PDR was also found in association analysis of 4,005 individuals with type 1 diabetes with an odds ratio of 0.83 and P value of 8.6 × 10(−4) for rs11014284. Sequencing of CACNB2 revealed two coding variants, R476C/rs202152674 and S502L/rs137886839. CACNB2 is abundantly expressed in retinal cells and encodes the β2 subunit of the L-type calcium channel. Blocking vascular endothelial growth factor (VEGF) by intravitreous anti-VEGF injections is a promising clinical therapy to treat PDR. Our data show that L-type calcium channels regulate VEGF expression and secretion from retinal pigment epithelial cells (ARPE19) and support the role of CACNB2 via regulation of VEGF in the pathogenesis of PDR. However, further genetic and functional studies are necessary to consolidate the findings. |
format | Online Article Text |
id | pubmed-6804633 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-68046332020-11-01 CACNB2 Is a Novel Susceptibility Gene for Diabetic Retinopathy in Type 1 Diabetes Vuori, Nadja Sandholm, Niina Kumar, Anmol Hietala, Kustaa Syreeni, Anna Forsblom, Carol Juuti-Uusitalo, Kati Skottman, Heli Imamura, Minako Maeda, Shiro Summanen, Paula A. Lehto, Markku Groop, Per-Henrik Diabetes Genetics/Genomes/Proteomics/Metabolomics Diabetic retinopathy is a common diabetes complication that threatens the eyesight and may eventually lead to acquired visual impairment or blindness. While a substantial heritability has been reported for proliferative diabetic retinopathy (PDR), only a few genetic risk factors have been identified. Using genome-wide sib pair linkage analysis including 361 individuals with type 1 diabetes, we found suggestive evidence of linkage with PDR at chromosome 10p12 overlapping the CACNB2 gene (logarithm of odds = 2.73). Evidence of association between variants in CACNB2 and PDR was also found in association analysis of 4,005 individuals with type 1 diabetes with an odds ratio of 0.83 and P value of 8.6 × 10(−4) for rs11014284. Sequencing of CACNB2 revealed two coding variants, R476C/rs202152674 and S502L/rs137886839. CACNB2 is abundantly expressed in retinal cells and encodes the β2 subunit of the L-type calcium channel. Blocking vascular endothelial growth factor (VEGF) by intravitreous anti-VEGF injections is a promising clinical therapy to treat PDR. Our data show that L-type calcium channels regulate VEGF expression and secretion from retinal pigment epithelial cells (ARPE19) and support the role of CACNB2 via regulation of VEGF in the pathogenesis of PDR. However, further genetic and functional studies are necessary to consolidate the findings. American Diabetes Association 2019-11 2019-08-22 /pmc/articles/PMC6804633/ /pubmed/31439644 http://dx.doi.org/10.2337/db19-0130 Text en © 2019 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license. |
spellingShingle | Genetics/Genomes/Proteomics/Metabolomics Vuori, Nadja Sandholm, Niina Kumar, Anmol Hietala, Kustaa Syreeni, Anna Forsblom, Carol Juuti-Uusitalo, Kati Skottman, Heli Imamura, Minako Maeda, Shiro Summanen, Paula A. Lehto, Markku Groop, Per-Henrik CACNB2 Is a Novel Susceptibility Gene for Diabetic Retinopathy in Type 1 Diabetes |
title | CACNB2 Is a Novel Susceptibility Gene for Diabetic Retinopathy in Type 1 Diabetes |
title_full | CACNB2 Is a Novel Susceptibility Gene for Diabetic Retinopathy in Type 1 Diabetes |
title_fullStr | CACNB2 Is a Novel Susceptibility Gene for Diabetic Retinopathy in Type 1 Diabetes |
title_full_unstemmed | CACNB2 Is a Novel Susceptibility Gene for Diabetic Retinopathy in Type 1 Diabetes |
title_short | CACNB2 Is a Novel Susceptibility Gene for Diabetic Retinopathy in Type 1 Diabetes |
title_sort | cacnb2 is a novel susceptibility gene for diabetic retinopathy in type 1 diabetes |
topic | Genetics/Genomes/Proteomics/Metabolomics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804633/ https://www.ncbi.nlm.nih.gov/pubmed/31439644 http://dx.doi.org/10.2337/db19-0130 |
work_keys_str_mv | AT vuorinadja cacnb2isanovelsusceptibilitygenefordiabeticretinopathyintype1diabetes AT sandholmniina cacnb2isanovelsusceptibilitygenefordiabeticretinopathyintype1diabetes AT kumaranmol cacnb2isanovelsusceptibilitygenefordiabeticretinopathyintype1diabetes AT hietalakustaa cacnb2isanovelsusceptibilitygenefordiabeticretinopathyintype1diabetes AT syreenianna cacnb2isanovelsusceptibilitygenefordiabeticretinopathyintype1diabetes AT forsblomcarol cacnb2isanovelsusceptibilitygenefordiabeticretinopathyintype1diabetes AT juutiuusitalokati cacnb2isanovelsusceptibilitygenefordiabeticretinopathyintype1diabetes AT skottmanheli cacnb2isanovelsusceptibilitygenefordiabeticretinopathyintype1diabetes AT imamuraminako cacnb2isanovelsusceptibilitygenefordiabeticretinopathyintype1diabetes AT maedashiro cacnb2isanovelsusceptibilitygenefordiabeticretinopathyintype1diabetes AT summanenpaulaa cacnb2isanovelsusceptibilitygenefordiabeticretinopathyintype1diabetes AT lehtomarkku cacnb2isanovelsusceptibilitygenefordiabeticretinopathyintype1diabetes AT groopperhenrik cacnb2isanovelsusceptibilitygenefordiabeticretinopathyintype1diabetes |